Live feed06:45:00·4mPRReleasevia QuantisnowU.S. FDA Accepts sBLA for ENFLONSIA™ (clesrovimab-cfor) to Update its Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease Indication to Include Children Under Two Years at Increased Risk for Severe RSV for Their Second SeasonByQuantisnow·Wall Street's wire, on your screen.MRK· Merck & Company Inc.Health Care
